ReviewInternational journal of pharmaceutics: X2026
Application and prospects of nanomaterials in osteoporosis treatment.
Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Polysaccharide-Mediated Nano-Delivery Systems for Osteoporosis Therapy From a Gut-Bone Axis Regulatory Perspective.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is characterized by uncoupled bone remodeling, microarchitectural deterioration, and impaired fracture or defect healing, resulting in increased fragility and a high lifetime fracture burden. Current pharmacotherapies can reduce fracture risk, yet their impact is constrained by systemic exposure, adherence limitations, and the lack of direct mechanical restoration in localized defects. Nanomaterial-enabled biomaterials provide a means to localize therapy, engineer the osteoporotic microenvironment, and deliver defect-specific structural support. Unlike platform- or strategy-specific summaries, this review establishes a pathology-to-design framework that integrates drug-delivery nanosystems (lipid, polymeric, and inorganic carriers with bone- or osteoclast-targeting chemistries) with implantable or injectable nanocomposites (metal, ceramic, polymer, and composite matrices). Synthesis and processing parameters (composition, porosity, and micro/nanostructure) and surface chemistry (ion doping, bioactive coatings, and affinity motifs) are explicitly linked to targeted applications, including remodeling-preserving modulation of osteoclast-osteoblast coupling, osteoimmune regulation, angiogenesis support, and spatiotemporally programmed release. Advanced multifunctional approaches, such as staged antiresorptive-to-anabolic delivery, micro/nanotopography-guided interface engineering, and pH/enzyme/thermal/electroactive responsive systems, are critically evaluated in terms of performance trade-offs and failure modes. A translation-oriented evaluation and clinical-readiness roadmap is presented, emphasizing harmonized efficacy endpoints, chemistry, manufacturing and controls (CMC) and quality-by-design (QbD) for scalability, regulatory tractability for combination products, and long-term safety of nano-additives and degradation products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.